CSEMS3 - Consensus on Management of Low-risk Thyroid Cancer

Friday, November 28, 2025

10:30 - 11:45 Toronto

Location: Room 201 A/B/C/D/E/F

Speaker(s)

Ralf Paschke, MD, PhD (he/him/his)

Professor
University of Calgary
Calgary, Alberta, Canada

Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Moderator(s)

Vicki Munro, MD FRCPC GDCE (she/her/hers)

Endocrinologist
Dalhousie University
Dalhousie University
Halifax, Nova Scotia, Canada

Disclosure(s): Abbott Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); CPD Network: Speaker/Honoraria (Ongoing); Dalhousie University Faculty of Medicine: Grant/Research Support (Ongoing); Dexcom: Speaker/Honoraria (Terminated); Novo Nordisk: Speaker/Honoraria (Terminated); Pendopharm: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Speaker(s)

Sam Wiseman, MD, FRCSC, FACS

Endocrine Surgeon
St. Paul's Hospital, Providence Health Care
University of British Columbia
Vancouver, British Columbia, Canada

Disclosure(s): sernova: Consultant (Ongoing), Speaker/Honoraria (Ongoing)
SANA GHAZNAVI, MD (she/her/hers)

Endocrinologist
University of Calgary
University of Calgary
Calgary, Alberta, Canada

Disclosure(s): Eisai: Advisory Board (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing); Pendopharm: Advisory Board (Ongoing)
MM

Marie-Hélène Massicotte, MD FRCPC (she/her/hers)

Professor
Université de Sherbrooke, Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada

Disclosure(s): AAA/Novartis: Speaker/Honoraria (Terminated); Bayer: Advisory Board (Terminated); Eisai: Advisory Board (Terminated); Ipsen: Speaker/Honoraria (Terminated)

Disclosure(s):

Ralf Paschke, MD, PhD: I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Vicki Munro, MD FRCPC GDCE: Abbott Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); CPD Network: Speaker/Honoraria (Ongoing); Dalhousie University Faculty of Medicine: Grant/Research Support (Ongoing); Dexcom: Speaker/Honoraria (Terminated); Novo Nordisk: Speaker/Honoraria (Terminated); Pendopharm: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Sam Wiseman, MD, FRCSC, FACS: sernova: Consultant (Ongoing), Speaker/Honoraria (Ongoing)

SANA GHAZNAVI, MD: Eisai: Advisory Board (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing); Pendopharm: Advisory Board (Ongoing)

Marie_Hélèn Massicotte: AAA/Novartis: Speaker/Honoraria (Terminated); Bayer: Advisory Board (Terminated); Eisai: Advisory Board (Terminated); Ipsen: Speaker/Honoraria (Terminated)

Learning Objectives: This session will:
1. Summarize the current international consensus guidelines on the diagnosis, risk stratification, and initial management of low-risk differentiated thyroid cancer, including criteria for active surveillance versus surgical intervention.
2. Critically evaluate the evidence supporting de-escalation strategies in low-risk thyroid cancer management, including reduced extent of surgery, selective use of radioactive iodine, and individualized TSH suppression targets.
3. Apply a patient-centered, evidence-based approach to counseling and managing individuals with low-risk thyroid cancer, incorporating shared decision-making principles and long-term surveillance strategies."

Learning Objectives:

Summarize the current Canadian consensus guidelines on the diagnosis, risk stratification, and initial management of low-risk differentiated thyroid cancer, including criteria for active surveillance versus surgical intervention;
Critically evaluate the evidence supporting de-escalation strategies in low-risk thyroid cancer management, including reduced extent of surgery, selective use of radioactive iodine, and individualized TSH suppression targets;
Apply a patient-centered, evidence-based approach to counseling and managing individuals with low-risk thyroid cancer, incorporating shared decision-making principles and long-term surveillance strategies.